• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Optogenetic stimulation: Solving challenge of controlling IOP


Lipid regulation within primary cilia may prove to be a solution for patients

A class of lipids in the trabecular meshwork reacts to changes in light intensity and may provide a pathway to regulating IOP in humans.

Reviewed by Yang Sun, MD, PhD

Is there a unifying factor that controls the IOP? To answer this question, Yang Sun, MD, PhD, a Stanford professor, and colleagues investigated boys with Lowe syndrome, an X-linked recessive oculo-cerebro-renal disease with an incidence of 1 in 500,000 individuals.

The rarity of the disease shows how critical the enzyme deficient in this disease is critical for normal development.

The affected children are born with glaucoma and cataracts. The mutation of the gene causes a lipid phosphatase defect that is critical for normal development. Dr. Sun is an associate professor of ophthalmology at Stanford University School of Medicine, Stanford, CA.

Possible link

Interesting findings in the previous five years have suggested that lipid regulation within primary cilia might represent a possible link between the regulation of cerebrospinal fluid and the regulation of IOP in the trabecular meshwork of the eye.

High-power microscopy studies have revealed the presence of a specific class of lipids and their regulatory enzymes on the inside membrane of trabecular meshwork cells, which might be involved in ciliary function.

According to Dr. Sun, the identification of the exact regulatory mechanism of lipid regulators and their influence in modulating IOP could prove significant in future approaches to influence and control elevated IOP and therefore glaucoma in children.

Dr. Sun theorized that IOP could be potentially regulated using a light inducible mechanism which allows to regulate the enzymatic activity in a time-dependent fashion. He explained that this idea arose in the wake of pioneering studies by Karl Deisseroth MD, PhD, another Stanford clinician-scientist, who found a way to activate neuronal cells using specific light-sensitive proteins, called optogenetics.

Light stimulation of a specific wavelength on these neurons resulted in the emission of a controlled electrical signal. This response could be used to control a desired activity by turning the electrical signal on and off.

RELATED: Ophthalmic year in reviewLight-controlled mouse model

“This is a really remarkable way of controlling function in an animal,” Dr. Sun commented.

This discovery prompted him to investigate the possibility to influence IOP in the same manner. The idea led to the creation of a light-sensitive construct that is based on the same gene which is mutated in Lowe syndrome and causes dysfunctional enzymatic activity. The goal was to target the enzymatic activity in a light-dependent manner to primary cilia, which are known for their role in pressure and flow sensation.

Research with a virus

Dr. Sun demonstrated that when the light was turned on, the targeted enzymatic activity resulted in a profound change in the cytoskeleton organization of the trabecular meshwork cells. A virus containing this light-controlled mechanism was subsequently used to introduce this system into a mouse eye.

The virus was designed to infect the trabecular meshwork cells, allowing the IOP-changing mechanism to unfold in this area which is so important in regulating outflow facility, Dr. Sun explained, noting that using this model, light dependent enzymatic activity resulted in a decrease in IOP while turning off the light reversed this IOP effect.

“These results showed that the regulation of phospholipid in the cells, could be actively harnessed to cause changes in cellular functions,” he added.
Over the last decade, a mouse model of Lowe syndrome was created, marking the first time the disease was studied in animal models. These animals are characterized by loss of the ganglion cells and defects in the outflow facility.

"When light dependent enzymatic activity activated in this model, it resulted in significant improvement of the outflow facility,” Dr. Sun said.

A similar effect was also observed in a steroid-induced glaucoma model developed in collaboration with investigators at Duke University, showing a reverse of elevated IOP after light-dependent enzymatic activation.

“We identified a particular class of lipids within the trabecular meshwork cells, which play a crucial role in regulating mechanisms related to IOP,” Dr. Sun added. “The role of primary cilia in this setting is of equally importance, due to their association with pressure changes sensation and as hubs for many of these lipid-signaling mechanisms”.

RELATED: Clinical teaching across the Atlantic: Learning in actionA new approach

The identification of a reusable and reversible way to control high pressure in mice, using light to specifically target the enzymatic activity to subcellular regions, is a new approach for the characterization of the mechanisms involved in IOP regulation.

This study highlighted the activity of this enzyme as a potential very promising target for future pharmaceutical applications.
“The current investigations are part of a larger preclinical animal model, which will be used to test this idea,” Dr. Sun concluded. This study received funding from the Veteran’s Administration and the National Eye Institute.

RELATED: Cataract surgeons adopting interventional glaucoma treatments


Yang Sun, MD, PhD
E: yangsun@stanford.edu
Dr. Sun has no financial connections to disclose

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.